Back to Investor Brief

Investor Brief · Part 2

Digital Strategy: architecture, motion, and moats

Pause is not just a product strategy — it's a category-creation strategy. The architecture and go-to-market are designed to compound defensibility from day one.

Architectural pillars

EHR-native, never sidecar

Pause is delivered as a SMART-on-FHIR app inside Epic and Cerner workflows. The clinician never leaves their chart. This single architectural choice is the difference between adopted product and shelfware.

Patient-side data capture

PRO and wearable data are collected via a mobile experience the patient already uses (HealthKit / Health Connect bridge), then surfaced as a structured 'pre-read' inside the EHR — not a separate inbox.

Recommendation, not autopilot

Pause never takes a clinical action. It surfaces a ranked, explainable recommendation set with cited evidence and an editable narrative. The clinician remains the decision maker.

Outcomes-anchored contracting

Every customer contract includes a measurement plan: diagnostic time, symptom resolution, HT adherence, avoidable utilization, satisfaction. We are paid in part on what we deliver.

Build the registry, own the evidence

The de-identified outcomes registry is published, contributing to the menopause evidence base, and circling back to product as the strongest competitive moat we have.

Go-to-market motion

Year 0 — design partners

3-5 forward-leaning IDNs and 1 value-based payer. Free or deeply discounted. Mutual goal: ship-quality clinical evidence and case studies. Co-author publications and conference talks.

Year 1 — paid pilots into ARR

Convert design partners to paid contracts. Land 3-5 new IDNs at $250-500k ACV. Begin payer pilots with PMPM structure. ARR target: $2-4M.

Year 2 — peer expansion

Lean on customer references and clinical advisory network. Expand within multi-system IDNs (single hospital → enterprise). Launch employer-paid carve-out via payer partners. ARR target: $10-15M.

Year 3 — platform extensions

Adjacent vertical: bone health, cardiometabolic risk, sexual / pelvic health for midlife women. Continue compounding outcomes data. ARR target: $30-45M.

Competitive moats

Workflow integration depth

Each Epic/Cerner deployment takes 60-120 days and meaningful clinician trust. Once installed, switching cost is high. Eventually, Pause becomes 'the way menopause care is done here.'

Outcomes registry

Continuous accumulation of structured outcomes data tied to specific recommendations. After 18 months of customer deployment, the registry is unreplicable by a new entrant.

Clinical advisory network

A who's-who of NAMS-affiliated clinicians and researchers as advisors and design partners. Each adds credibility and slows competitive entry.

Guideline grounding library

A curated, structured, retrievable corpus of menopause guidelines maintained as evidence evolves. The work of building and maintaining it is more durable than the AI models themselves.

Brand and category leadership

Owning 'menopause AI for providers' as a category. First in market, loudest voice in clinical conferences, deepest evidence base.

Operating principles